As for OSCC, extensive research in preclinical and clinical settings has shown that EGFR activation leads to the stimulation of proliferative and pro-survival intracellular signaling pathways, such as Mitogen-activated protein kinases (MAPKs) cascade, Phosphoinositide-3 kinase (PI3K)/Akt kinase (AKT)/Mammalian target of rapamycin (mTOR), and the Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) pathway, resulting in increased tumor invasion and metastasis [6,10,11]. Here, MTOR is linked to neoplasm.